enGene Therapeutics Inc. SEC filings ENGNW
enGene Therapeutics Inc. has 267 filings in SEC EDGAR's recent list, going back to Jun 14, 2023. Its latest annual report, Form ARS, was filed on May 8, 2026 for the period ended Oct 31, 2025. The latest quarterly report (Form 10-Q) was filed on Sep 8, 2026, covering the quarter ended Jul 31, 2026. The most recent current report (Form 8-K) was filed on Sep 8, 2026 (results of operations). The company's fiscal year ends on October 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Sep 24, 2026 | Sep 22, 2026 |
| 10-Q | Quarterly report | Sep 8, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 8, 2026 | Sep 8, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 13, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 12, 2026 | — |
| 8-K |
Current report
Other events
|
Aug 11, 2026 | Aug 11, 2026 |
| 3 | Initial insider ownership | Jul 22, 2026 | Jul 16, 2026 |
| 3 | Initial insider ownership | Jul 22, 2026 | Jul 16, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 22, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 17, 2026 | Jul 17, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 16, 2026 | Jul 15, 2026 |
| 8-K/A |
Amended current report
Exit or restructuring costs, Officer or director change
|
Jun 18, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 17, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 17, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 17, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 17, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 17, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 17, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 17, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 17, 2026 | Jun 16, 2026 |
| 10-Q | Quarterly report | Jun 15, 2026 | Apr 30, 2026 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Officer or director change, Regulation FD disclosure, Other events
|
Jun 15, 2026 | Jun 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2026 | Jun 9, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 14, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 13, 2026 | — |
| ARS | Annual report to shareholders | May 8, 2026 | Oct 31, 2025 |
| DEF 14A | Proxy statement | May 8, 2026 | Jun 9, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure, Other events
|
May 7, 2026 | May 5, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 5, 2026 | — |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure
|
Apr 9, 2026 | Apr 7, 2026 |
| S-8 | Employee stock plan registration | Mar 9, 2026 | — |
| 424B5 | Prospectus supplement | Mar 9, 2026 | — |
| 8-K |
Current report
Material agreement, Agreement ended
|
Mar 9, 2026 | Mar 9, 2026 |
| 10-Q | Quarterly report | Mar 9, 2026 | Jan 31, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 9, 2026 | Mar 9, 2026 |
| EFFECT | Filing | Mar 2, 2026 | — |
| CORRESP | Letter to the SEC | Feb 26, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 25, 2026 | — |
| S-3 | Shelf registration | Feb 19, 2026 | — |
| 10-K/A | Amended annual report | Feb 19, 2026 | Oct 31, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| 4 | Insider transaction | Feb 3, 2026 | Jan 30, 2026 |
| 4 | Insider transaction | Feb 3, 2026 | Jan 30, 2026 |
| 4 | Insider transaction | Feb 3, 2026 | Jan 30, 2026 |
| 4 | Insider transaction | Feb 3, 2026 | Jan 30, 2026 |
| 4 | Insider transaction | Feb 3, 2026 | Jan 30, 2026 |
| 4 | Insider transaction | Feb 3, 2026 | Jan 30, 2026 |
| 4 | Insider transaction | Feb 3, 2026 | Jan 30, 2026 |
| 4 | Insider transaction | Feb 3, 2026 | Jan 30, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 27, 2026 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jan 21, 2026 | Jan 20, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 21, 2026 | Jan 20, 2026 |
| 10-K | Annual report | Dec 22, 2025 | Oct 31, 2025 |
| 8-K |
Current report
Results of operations
|
Dec 22, 2025 | Dec 22, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 18, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 18, 2025 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Nov 14, 2025 | Nov 12, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| 424B5 | Prospectus supplement | Nov 14, 2025 | — |
| 424B5 | Prospectus supplement | Nov 12, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 12, 2025 | Nov 11, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 2, 2025 | Oct 2, 2025 |
| 8-K/A |
Amended current report
Officer or director change
|
Oct 2, 2025 | Jul 7, 2025 |
| 4 | Insider transaction | Oct 1, 2025 | Sep 30, 2025 |
| 3 | Initial insider ownership | Oct 1, 2025 | Sep 29, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 30, 2025 | Sep 30, 2025 |
| S-8 | Employee stock plan registration | Sep 11, 2025 | — |
| 10-Q | Quarterly report | Sep 11, 2025 | Jul 31, 2025 |
| 8-K |
Current report
Results of operations
|
Sep 11, 2025 | Sep 11, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 3, 2025 | Sep 3, 2025 |
| 4 | Insider transaction | Jul 14, 2025 | Jul 8, 2025 |
| 3 | Initial insider ownership | Jul 14, 2025 | Jul 8, 2025 |
| 4 | Insider transaction | Jul 10, 2025 | Jul 8, 2025 |
| 4 | Insider transaction | Jul 10, 2025 | Jul 8, 2025 |
| 4 | Insider transaction | Jul 10, 2025 | Jul 8, 2025 |
| 4 | Insider transaction | Jul 10, 2025 | Jul 8, 2025 |
| 3 | Initial insider ownership | Jul 8, 2025 | Jul 8, 2025 |
| 3 | Initial insider ownership | Jul 8, 2025 | Jul 8, 2025 |
| 3 | Initial insider ownership | Jul 8, 2025 | Jul 8, 2025 |
| 3 | Initial insider ownership | Jul 8, 2025 | Jul 8, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 8, 2025 | Jul 7, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 16, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 16, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 16, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 16, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 16, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 16, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 16, 2025 |
| 10-Q | Quarterly report | Jun 12, 2025 | Apr 30, 2025 |
| 8-K |
Current report
Results of operations
|
Jun 12, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 10, 2025 | Jun 10, 2025 |
| 8-K |
Current report
Material agreement, New debt
|
Jun 9, 2025 | Jun 4, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 4, 2025 | Jun 3, 2025 |
| 3 | Initial insider ownership | May 29, 2025 | May 27, 2025 |
| ARS | Annual report to shareholders | May 9, 2025 | Oct 31, 2024 |
| DEF 14A | Proxy statement | May 9, 2025 | Jun 10, 2025 |
| S-8 | Employee stock plan registration | Mar 10, 2025 | — |
| 10-Q | Quarterly report | Mar 10, 2025 | Jan 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 10, 2025 | Mar 10, 2025 |
| 10-K/A | Amended annual report | Feb 20, 2025 | Oct 31, 2024 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 12, 2025 | — |
| 4 | Insider transaction | Jan 31, 2025 | Jan 29, 2025 |
| 4 | Insider transaction | Jan 31, 2025 | Jan 29, 2025 |
| 4 | Insider transaction | Jan 31, 2025 | Jan 29, 2025 |
| 4 | Insider transaction | Jan 31, 2025 | Jan 29, 2025 |
| 4 | Insider transaction | Jan 31, 2025 | Jan 29, 2025 |
| 4 | Insider transaction | Jan 31, 2025 | Jan 29, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 29, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 29, 2025 | — |
| 8-K |
Current report
Material agreement
|
Dec 20, 2024 | Dec 20, 2024 |
| 424B5 | Prospectus supplement | Dec 20, 2024 | — |
| 10-K | Annual report | Dec 19, 2024 | Oct 31, 2024 |
| 8-K |
Current report
Material agreement, Results of operations, New debt
|
Dec 19, 2024 | Dec 19, 2024 |
| EFFECT | Filing | Nov 21, 2024 | — |
| EFFECT | Filing | Nov 21, 2024 | — |
| 424B3 | Prospectus | Nov 21, 2024 | — |
| 424B3 | Prospectus | Nov 21, 2024 | — |
| CORRESP | Letter to the SEC | Nov 19, 2024 | — |
| CORRESP | Letter to the SEC | Nov 19, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 18, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 18, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| S-3 | Shelf registration | Nov 13, 2024 | — |
| S-3 | Shelf registration | Nov 13, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Nov 12, 2024 | — |
| 4 | Insider transaction | Nov 1, 2024 | Oct 30, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Nov 1, 2024 | — |
| 424B3 | Prospectus | Oct 28, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Oct 25, 2024 | Oct 24, 2024 |
| 4 | Insider transaction | Oct 22, 2024 | Oct 21, 2024 |
| 4 | Insider transaction | Oct 22, 2024 | Oct 21, 2024 |
| 3 | Initial insider ownership | Oct 22, 2024 | Oct 21, 2024 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 21, 2024 | — |
| 424B3 | Prospectus | Oct 21, 2024 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure, Other events
|
Oct 21, 2024 | Oct 16, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Oct 18, 2024 | — |
| 4 | Insider transaction | Oct 18, 2024 | Dec 27, 2023 |
| 4 | Insider transaction | Oct 1, 2024 | Sep 27, 2024 |
| 424B3 | Prospectus | Sep 26, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 26, 2024 | Sep 26, 2024 |
| 424B3 | Prospectus | Sep 10, 2024 | — |
| 10-Q | Quarterly report | Sep 10, 2024 | Jul 31, 2024 |
| 8-K |
Current report
Results of operations
|
Sep 10, 2024 | Sep 10, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 5, 2024 | Sep 5, 2024 |
| 4 | Insider transaction | Jul 25, 2024 | Jul 24, 2024 |
| 3 | Initial insider ownership | Jul 25, 2024 | Jul 22, 2024 |
| 4 | Insider transaction | Jul 24, 2024 | Jul 22, 2024 |
| 3 | Initial insider ownership | Jul 24, 2024 | Jul 22, 2024 |
| 424B3 | Prospectus | Jul 24, 2024 | — |
| 8-K |
Current report
Officer or director change, Other events
|
Jul 24, 2024 | Jul 22, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 15, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 15, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 15, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 15, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 15, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 15, 2024 |
| 424B3 | Prospectus | Jun 14, 2024 | — |
| 10-Q | Quarterly report | Jun 14, 2024 | Apr 30, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jun 14, 2024 | Jun 14, 2024 |
| 4 | Insider transaction | May 29, 2024 | May 28, 2024 |
| 3 | Initial insider ownership | May 17, 2024 | May 15, 2024 |
| 3 | Initial insider ownership | May 17, 2024 | May 15, 2024 |
| 424B3 | Prospectus | May 15, 2024 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 15, 2024 | May 15, 2024 |
| 424B3 | Prospectus | Apr 25, 2024 | — |
| 4 | Insider transaction | Apr 22, 2024 | Apr 18, 2024 |
| ARS | Annual report to shareholders | Apr 18, 2024 | Oct 31, 2023 |
| DEF 14A | Proxy statement | Apr 18, 2024 | May 15, 2024 |
| 4 | Insider transaction | Mar 25, 2024 | Mar 21, 2024 |
| 4 | Insider transaction | Mar 20, 2024 | Mar 18, 2024 |
| 4 | Insider transaction | Mar 19, 2024 | Mar 15, 2024 |
| 424B3 | Prospectus | Mar 12, 2024 | — |
| 10-Q | Quarterly report | Mar 11, 2024 | Jan 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 11, 2024 | Mar 11, 2024 |
| EFFECT | Filing | Mar 5, 2024 | — |
| 424B3 | Prospectus | Mar 5, 2024 | — |
| CORRESP | Letter to the SEC | Mar 4, 2024 | — |
| S-8 | Employee stock plan registration | Feb 27, 2024 | — |
| S-1/A | Amended registration statement | Feb 27, 2024 | — |
| CORRESP | Letter to the SEC | Feb 26, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 26, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 23, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 23, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 22, 2024 | — |
| 4 | Insider transaction | Feb 21, 2024 | Feb 20, 2024 |
| 4 | Insider transaction | Feb 21, 2024 | Feb 20, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Feb 21, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ENGN (Nasdaq), ENGNW (Nasdaq)
- Fiscal year ends
- October 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Saint-Laurent
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1980845
- Former names
- enGene Holdings Inc. (until Mar 9, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.